Pharma in China: Successful in the Healthcare Market
SCHREINER GROUP
Pharma in China:
Successful in the Healthcare Market
In 2016, Schreiner Group opened a production facility in China that started out by primarily supplying products to customers in the automotive industry. The expansion marked a major move for the medium-sized company. Since many of Schreiner Group’s customers are global corporations with international operations the ability to serve them quickly and at the level of top quality to which they were accustomed through local manufacturing was an important objective. And that plan worked out. The company’s Asian customers are thrilled by the German quality. Consequently, it’s hardly surprising that a second business unit of Schreiner Group, i.e. Schreiner MediPharm, has established itself at the Chinese location from where it successfully addresses the healthcare market.
Due to its fast growth, the plant near Shanghai moved from Fengpu to Jinshan about a year ago, making optimal use of the larger facilities there. In the modern factory hall, pharmaceutical production is now continually being expanded in order to support customers in the healthcare sector locally as effectively as possible. The local Chinese Schreiner MediPharm team provides optimal support and advice to the Chinese customers and through professional appearances at various trade fairs and congresses, etc. ensures that the company’s outstanding product portfolio is becoming increasingly well-known and desirable.
“As a strategic partner for the healthcare industry, we offer our international customers innovative solutions and services that particularly serve product and patient safety,” explains President Dr. Thomas Schweizer. With its high solutions expertise and in-depth know-how, Schreiner MediPharm is a highly capable development partner and reliable quality supplier to the major pharmaceutical companies around the world and now increasingly scores also with Chinese customers due to intensive exchange. “Our team analyzes the market-specific needs and requirements in detail and based on that analysis designs our products and services in application-specific and customized form for the Chinese market,” Schweizer reports. A reliable blinding solution for vials of the company WuXi STA is a case in point.
In general, the product portfolio is perceived very positively in China: Schreiner MediPharm, for instance, won the InnoPack Silver Award 2022 in the “Cost-Effective” category for its Needle-Trap needle protection label. The award ceremony took place at CPHI China 2023. Expressing his pleasure about the accolade, Schweizer said, “The award emphasizes that Needle-Trap is perceived as an innovative product with value-adding benefits also in the Chinese market.”
